StockMacro
Menu

Capricor Therapeutics

$7.59 -74% in 6 monthsMarket cap $441.3M

CAPR on XNAS, Health Care, Capricor Therapeutics Inc, job postings

Measures activity, not value. Not investment advice.

Shares up 29% in a month after falling 74% in six months, while 32% of shares sit short.

  • BadFree cash flow of -$132.7M over 12 months, against $197.6M cash
  • WatchNews ran 55 articles in seven days, 12.2 times its usual week

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Industry
Pharmaceutical preparations (Health Care)
Employees
231
Website
capricor.com
Listed
Nasdaq, US
Last results
10 Nov 2026
Next results
expected around 11 Mar 2027 (an estimate: a year ago it reported on 12 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $42.7M.
Quarter to 31 Dec 2021: revenue –, net income -$6.2MQuarter to 31 Mar 2022: revenue –, net income -$7.8MQuarter to 30 Jun 2022: revenue –, net income -$7.1MQuarter to 30 Sep 2022: revenue $1.6M, net income -$6.4MQuarter to 30 Sep 2022: revenue $1.6M, net income -$6.4MQuarter to 31 Dec 2022: revenue $960K, net income -$7.7MQuarter to 31 Dec 2022: revenue $960K, net income -$7.7MQuarter to 31 Mar 2023: revenue $3.0M, net income -$7.8MQuarter to 31 Mar 2023: revenue $3.0M, net income -$7.8MQuarter to 30 Jun 2023: revenue $3.9M, net income -$7.4MQuarter to 30 Jun 2023: revenue $3.9M, net income -$7.4MQuarter to 30 Sep 2023: revenue $6.2M, net income -$6.4MQuarter to 30 Sep 2023: revenue $6.2M, net income -$6.4MQuarter to 31 Dec 2023: revenue $12.1M, net income -$762KQuarter to 31 Dec 2023: revenue $12.1M, net income -$762KQuarter to 31 Mar 2024: revenue $4.9M, net income -$9.8MQuarter to 31 Mar 2024: revenue $4.9M, net income -$9.8MQuarter to 30 Jun 2024: revenue $4.0M, net income -$11.0MQuarter to 30 Jun 2024: revenue $4.0M, net income -$11.0MQuarter to 30 Sep 2024: revenue $2.3M, net income -$12.6MQuarter to 30 Sep 2024: revenue $2.3M, net income -$12.6MQuarter to 31 Dec 2024: revenue $11.1M, net income -$7.1MQuarter to 31 Dec 2024: revenue $11.1M, net income -$7.1MQuarter to 31 Mar 2025: revenue –, net income -$24.4MQuarter to 30 Jun 2025: revenue –, net income -$25.9MQuarter to 30 Sep 2025: revenue –, net income -$24.6MQuarter to 31 Dec 2025: revenue –, net income -$30.2MQuarter to 31 Mar 2026: revenue –, net income -$33.9MQuarter to 30 Jun 2026: revenue –, net income -$40.7MQuarter to 30 Sep 2026: revenue –, net income -$42.7M
31 Dec 2021RevenueNet incomeNet losstallest bar $42.7M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$42.7M
30 Jun 2026–-$40.7M
31 Mar 2026–-$33.9M
31 Dec 2025–-$30.2M
30 Sep 2025–-$24.6M
30 Jun 2025–-$25.9M
31 Mar 2025–-$24.4M
31 Dec 2024$11.1M-$7.1M
30 Sep 2024$2.3M-$12.6M
30 Jun 2024$4.0M-$11.0M
31 Mar 2024$4.9M-$9.8M
31 Dec 2023$12.1M-$762K
30 Sep 2023$6.2M-$6.4M
30 Jun 2023$3.9M-$7.4M
31 Mar 2023$3.0M-$7.8M
31 Dec 2022$960K-$7.7M
30 Sep 2022$1.6M-$6.4M
30 Jun 2022–-$7.1M
31 Mar 2022–-$7.8M
31 Dec 2021–-$6.2M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$147.5M -$82.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$2.64 -$1.75
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -100% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$132.7M –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $197.6M $98.6M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$197.6M (net cash) -$98.6M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $3.61
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 2.1 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Capricor TherapeuticsCAPR (this company) $441.3Mloss–––
Lyell ImmunopharmaLYEL $441.8Mlossover 999-63%–
CytomX TherapeuticsCTMX $442.5Mloss31.5-88%-609%
DiaMedica TherapeuticsDMAC $445.1Mloss–––
Aquestive TherapeuticsAQST $434.9Mloss8.9+13%-162%
Indaptus TherapeuticsINDP $433.2Mloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-6.6%

156 13F filers vs 167

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

69%

40.2M shares held by 13F filers (30 Sep 2026) of 58.1M outstanding (9 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

32%

18.8M shares sold short (30 Oct 2026) of 58.1M outstanding (9 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

7.4

18.8M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-5.5%

19.9M shares sold short in the report before, 18.8M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

65%

65% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 52%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

12

Tracked since 20 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 20 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$110K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

70

70 articles in the last 7 days; its usual week has 5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

14×

70 articles in the last 7 days; its usual week has 5.

Unusual now sharp changes in the last 90 days, compared with its own past

  • First lobbying new, first

Price $7.59 on 20 Nov 2026, +33% over 12 months (12-month range $3.85 to $35.34)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $8.4M in the last 12 months (the 12 months before: $0).
Revenue per quarter. Revenue $11.1M in the latest quarter, -7.9% on a year earlier.
Capital spending per quarter. Capital spending $1.8M in the latest quarter, +3145% on a year earlier.
Institutional holders (13F filers). 156 13F filers reported holding it in the latest 13F quarter, +42% on a year earlier.
Lobbying spend. Lobbying spend: $110K published in the last 12 months (none in the 12 months before).

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
26 Aug 2026Lobbying filingnew lobbying registration (CHECKMATE GOVERNMENT RELATIONS)
26 Aug 2026Sharp changeFirst lobbying registration: first lobbying registration: CAPRICOR THERAPEUTICS: new lobbying registration (CHECKMATE GOVERNMENT RELATIONS)
19 May 2026Sharp changeMany funds opening a new position: many funds opening a new position, 59 vs usual 27 (2026-03-31); 2.0x the same period a year earlier
14 May 2026Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 5.1M vs usual 388K (2026-03-31); 5.7x the same period a year earlier
27 May 20258-K and other filingsDirector or officer change
8 Apr 20258-K and other filingsDirector or officer change
8 Apr 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Feb 2025Sharp changeMany funds opening a new position: many funds opening a new position, 44 vs usual 5 (2024-12-31); 8.8x the same period a year earlier
19 Nov 2024Sharp changeMany funds opening a new position: many funds opening a new position, 25 vs usual 5 (2024-09-30); 6.2x the same period a year earlier
21 May 2024Sharp changeMany funds opening a new position: many funds opening a new position, 25 vs usual 5 (2024-03-31); 5.0x the same period a year earlier
16 Apr 2024Sharp changeShort interest spike: short interest spike, 3.5M vs usual 608K (2024-03-28); 12.7x the same period a year earlier
2 Apr 2024Sharp changeShort interest spike: short interest spike, 3.2M vs usual 474K (2024-03-15); 9.1x the same period a year earlier
12 Mar 2024Sharp changeQuarterly revenue change: quarterly revenue change, 12.1M vs usual 1.6M (2023-12-31); 12.6x the same period a year earlier
12 Mar 2024Sharp changeShort interest spike: short interest spike, 2.7M vs usual 377K (2024-02-29); 8.0x the same period a year earlier
5 Mar 2024Sharp changeShort interest spike: short interest spike, 2.7M vs usual 346K (2024-02-15); 8.6x the same period a year earlier
13 Feb 2024Sharp changeShort interest spike: short interest spike, 2.7M vs usual 333K (2024-01-31); 8.2x the same period a year earlier
30 Jan 2024Sharp changeShort interest spike: short interest spike, 2.7M vs usual 333K (2024-01-12); 7.8x the same period a year earlier
16 Jan 2024Sharp changeShort interest spike: short interest spike, 2.4M vs usual 333K (2023-12-29); 6.9x the same period a year earlier
2 Jan 2024Sharp changeShort interest spike: short interest spike, 2.1M vs usual 322K (2023-12-15); 6.8x the same period a year earlier
12 Dec 2023Sharp changeShort interest spike: short interest spike, 1.5M vs usual 314K (2023-11-30); 6.1x the same period a year earlier
28 Nov 2023Sharp changeShort interest spike: short interest spike, 1.4M vs usual 311K (2023-11-15); 5.2x the same period a year earlier
14 Nov 2023Sharp changeShort interest spike: short interest spike, 1.2M vs usual 303K (2023-10-31); 5.0x the same period a year earlier
31 Oct 2023Sharp changeShort interest spike: short interest spike, 1.2M vs usual 296K (2023-10-13); 4.1x the same period a year earlier
17 Oct 2023Sharp changeShort interest spike: short interest spike, 669K vs usual 296K (2023-09-29); 2.0x the same period a year earlier
3 Oct 2023Sharp changeShort interest spike: short interest spike, 548K vs usual 286K (2023-09-15); 2.6x the same period a year earlier
6 Sep 20238-K and other filingsDirector or officer change
24 Jul 20238-K and other filingsDirector or officer change
13 Jul 20238-K and other filingsDirector or officer change
13 Jul 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Jun 2022: -$79K published
Month from 1 Jul 2022: -$97K published
Month from 1 Apr 2023: -$12K published
Month from 1 Oct 2023: $65K published
Month from 1 Sep 2024: $15.0M published
Month from 1 Apr 2026: -$5.3M published
Month from 1 May 2026: -$1.6M published
Month from 1 Jun 2026: -$1.5M published
Revenue per quarter
Quarter ended 30 Sep 2022: $1.6M; public on 11 Nov 2022
Quarter ended 31 Dec 2022: $960K; public on 18 Mar 2023
Quarter ended 31 Mar 2023: $3.0M; public on 13 May 2023
Quarter ended 30 Jun 2023: $3.9M; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $6.2M, +289% on a year earlier; public on 15 Nov 2023
Quarter ended 31 Dec 2023: $12.1M, +1159% on a year earlier; public on 12 Mar 2024
Quarter ended 31 Mar 2024: $4.9M, +64% on a year earlier; public on 15 May 2024
Quarter ended 30 Jun 2024: $4.0M, +1.4% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $2.3M, -63% on a year earlier; public on 15 Nov 2024
Quarter ended 31 Dec 2024: $11.1M, -7.9% on a year earlier; public on 27 Mar 2025
Capital spending per quarter
Quarter ended 31 Dec 2021: $369K, +28% on a year earlier; public on 12 Mar 2022
Quarter ended 31 Mar 2022: $568K, +1438% on a year earlier; public on 12 May 2022
Quarter ended 30 Jun 2022: $181K, -44% on a year earlier; public on 13 Aug 2022
Quarter ended 30 Sep 2022: $558K, +19% on a year earlier; public on 11 Nov 2022
Quarter ended 31 Dec 2022: $694K, +88% on a year earlier; public on 18 Mar 2023
Quarter ended 31 Mar 2023: $348K, -39% on a year earlier; public on 13 May 2023
Quarter ended 30 Jun 2023: $136K, -25% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $269K, -52% on a year earlier; public on 15 Nov 2023
Quarter ended 31 Dec 2023: $559K, -20% on a year earlier; public on 12 Mar 2024
Quarter ended 31 Mar 2024: $609K, +75% on a year earlier; public on 15 May 2024
Quarter ended 30 Jun 2024: $60K, -56% on a year earlier; public on 9 Aug 2024
Quarter ended 31 Mar 2025: $896K, +47% on a year earlier; public on 15 May 2025
Quarter ended 30 Jun 2025: $288K, +377% on a year earlier; public on 12 Aug 2025
Quarter ended 30 Sep 2025: $56K; public on 11 Nov 2025
Quarter ended 31 Dec 2025: $1.7M; public on 18 Mar 2026
Quarter ended 31 Mar 2026: $5.1M, +472% on a year earlier; public on 14 May 2026
Quarter ended 30 Jun 2026: $4.1M, +1312% on a year earlier; public on 15 Aug 2026
Quarter ended 30 Sep 2026: $1.8M, +3145% on a year earlier; public on 11 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 23; public on 14 Feb 2022
31 Mar 2022 report: 28; public on 16 May 2022
30 Jun 2022 report: 27; public on 15 Aug 2022
30 Sep 2022 report: 27; public on 14 Nov 2022
31 Dec 2022 report: 30; public on 14 Feb 2023
31 Mar 2023 report: 28; public on 15 May 2023
30 Jun 2023 report: 29; public on 14 Aug 2023
30 Sep 2023 report: 31; public on 14 Nov 2023
31 Dec 2023 report: 33; public on 14 Feb 2024
31 Mar 2024 report: 56; public on 15 May 2024
30 Jun 2024 report: 56; public on 14 Aug 2024
30 Sep 2024 report: 72; public on 14 Nov 2024
31 Dec 2024 report: 108; public on 14 Feb 2025
31 Mar 2025 report: 118; public on 15 May 2025
30 Jun 2025 report: 103; public on 14 Aug 2025
30 Sep 2025 report: 110; public on 14 Nov 2025
31 Dec 2025 report: 127; public on 17 Feb 2026
31 Mar 2026 report: 172; public on 15 May 2026
30 Jun 2026 report: 167; public on 14 Aug 2026
30 Sep 2026 report: 156; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Oct 2026: $110K published

What is unusual now

  • Made public in the last 90 days: it registered for federal lobbying for the first time in our data (Checkmate Government Relations).
  • First lobbying registration: registered for federal lobbying for the first time in our data (Checkmate Government Relations) Public on 26 Aug 2026.
  • Insider net buying (open market): Insiders sold a net $8.4M in the last 12 months (the 12 months before: $0).
  • Revenue per quarter: Revenue $11.1M in the latest quarter, -7.9% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 33 insider trades

No trades in the last 90 days; the latest was filed 29 Jun 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
29 Jun 2026Anthony BergmannCHIEF FINANCIAL OFFICERSellafter exercising options24,100$30.38$732KForm 4
29 Jun 2026Karen KrasneyEVP, GENERAL COUNSELSellafter exercising options24,100$30.38$732KForm 4
24 Jun 2026Anthony BergmannCHIEF FINANCIAL OFFICERSellafter exercising options900$30.00$27KForm 4
24 Jun 2026Karen KrasneyEVP, GENERAL COUNSELSellafter exercising options900$30.00$27KForm 4
4 May 2026Anthony BergmannCHIEF FINANCIAL OFFICERSellplanned in advance (10b5-1); after exercising options25,000$31.70$792KForm 4
4 May 2026Karen KrasneyEVP, GENERAL COUNSELSellplanned in advance (10b5-1); after exercising options25,000$31.70$792KForm 4
3 Apr 2026Karimah Es SabarDirectorSellplanned in advance (10b5-1); after exercising options7,529$32.00$241KForm 4
1 Apr 2026Karen KrasneyEVP, GENERAL COUNSELSellplanned in advance (10b5-1); after exercising options25,000$30.12$753KForm 4

156 institutions reported shares at the end of Q3 2026, 69% of the shares outstanding; 34 opened a position, 44 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.4.2M7.19%$39.6M+33K+0.8%
State Street Corp3.0M5.19%$28.6M-378K-11%
Ra Capital Management, L.P.3.0M5.18%$28.5M+1.5M+100%
Vanguard Capital Management LLC2.3M3.96%$21.8M+5,707+0.2%
D. E. Shaw & Co., Inc.2.1M3.68%$20.3M+2.0M17 times as many
Millennium Management LLC1.7M2.87%$15.8M+1.4M+614%
UBS Group AG1.4M2.41%$13.3M+784K+126%
EcoR1 Capital, LLC1.4M2.37%$13.0MNew+1.4M
Longaeva Partners L.P.1.2M2.12%$11.7M+1.2M17 times as many
Geode Capital Management, LLC1.1M1.96%$10.8M-235K-17%

Company events

All 41 company events

In 12 months: 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
14 Jul 2026Signed a major agreementSame filing: took on new debt8-K
27 May 2025Director or officer changeSame filing: shareholder vote results8-K
8 Apr 2025Director or officer change8-K
17 Oct 2024Signed a major agreement8-K
17 Sep 2024Signed a major agreementSame filing: sold shares privately8-K
29 Sep 2023Signed a major agreement8-K
6 Sep 2023Director or officer change8-K
24 Jul 2023Director or officer change8-K

12 open postings; careers site tracked since 20 Nov 2026. Most in Legal, policy & compliance 25%, Finance & accounting 17%, People & recruiting 17%, Corporate IT 8%.

PostedJobLocation
10 Nov 2026Senior Director, Field ReimbursementPeople & recruitingRemote
6 Nov 2026Senior Director, Head of Payer Strategy & EngagementPeople & recruitingRemote
6 Nov 2026Quality Assurance Associate II - Night ShiftFinance & accountingSan Diego, CA
2 Nov 2026Quality Control Associate - Environmental MonitoringTest, quality & reliabilitySan Diego, CA
29 Oct 2026Senior Director, Head of Commercial OperationsOperations & administrationRemote
29 Oct 2026Senior Director, Head of Patient ServicesLegal, policy & complianceRemote
27 Oct 2026Associate Director, Cost AccountingFinance & accountingSan Diego, CA
27 Oct 2026ParalegalLegal, policy & complianceSan Diego, CA

Reported lobbying spend: $110K in Q3 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
20 Jul 2026NewCheckmate Government Relationsfor Capricor TherapeuticsIssues related to rare disease therapeutic developmentHealth issuesFiling

The 5 newest of 393 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

19 May 2026confirmed

Confirmed across sources Institutional holdings and Filings + Financials

Capricor Therapeutics (CAPR): spent $5.1M on capital projects in the quarter ended 31 Mar 2026, 5.7× the same quarter last year, while it saw 59 13F filers open a new position in the quarter ended 31 Mar 2026, 2.0× the same quarter last year. Two unrelated kinds of activity within 5 days.

  • Financials: Quarterly capital spending jump, became public on 14 May 2026
  • Institutional holdings: Many funds opening a new position, became public on 15 May 2026
2024-03-31: $609K2024-06-30: $60K2024-09-30: $9K2024-12-31: $489K2025-03-31: $896K2025-06-30: $288K2025-09-30: $56K2025-12-31: $1.7M2026-03-31: $5.1M
The quarter ended 31 Mar 2026 against the 8 quarters before it. this quarterearliernormal: $388K
See the evidence (2 changes)

Financials: Quarterly capital spending jump became public on 14 May 2026

Capricor Therapeutics spent $5.1M on capital projects in the quarter ended 31 Mar 2026, 5.7× the same quarter last year.

This period
$5.1M (the quarter ended 31 Mar 2026)
Normal quarter (median of 8 earlier)
$388K
Typical spread (median absolute deviation)
$330K
How far from its usual level
+4.7
Same quarter last year
$896K
History used
3,652 days
2024-03-31: $609K2024-06-30: $60K2024-09-30: $9K2024-12-31: $489K2025-03-31: $896K2025-06-30: $288K2025-09-30: $56K2025-12-31: $1.7M2026-03-31: $5.1M
the quarter ended 31 Mar 20268 earlier quartersnormal: $388K

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Institutional holdings: Many funds opening a new position became public on 15 May 2026

Capricor Therapeutics saw 59 13F filers open a new position in the quarter ended 31 Mar 2026, 2.0× the same quarter last year.

This period
59 (the quarter ended 31 Mar 2026)
Normal quarter (median of 8 earlier)
27
Typical spread (median absolute deviation)
6
How far from its usual level
+3.6
Same quarter last year
29
History used
4,018 days
2024-03-31: 252024-06-30: 182024-09-30: 252024-12-31: 442025-03-31: 292025-06-30: 142025-09-30: 302025-12-31: 402026-03-31: 59
the quarter ended 31 Mar 20268 earlier quartersnormal: 27

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

12 Mar 2024confirmed

Confirmed across sources Filings + Financials and Short interest and volume

Capricor Therapeutics (CAPR): reported revenue of $12.1M for the quarter ended 31 Dec 2023, 13× the same quarter last year, while it had 3.2M shares sold short in the 15 Mar 2024 report, 9.1× the same report last year. Two unrelated kinds of activity within 63 days.

  • Short interest and volume: Short interest spike, became public on 10 Feb 2024
  • Short interest and volume: Short interest spike, became public on 28 Feb 2024
  • Financials: Quarterly revenue change, became public on 12 Mar 2024
  • Short interest and volume: Short interest spike, became public on 12 Mar 2024
  • Short interest and volume: Short interest spike, became public on 27 Mar 2024
  • Short interest and volume: Short interest spike, became public on 10 Apr 2024
2021-03-31: $41K2021-06-30: $204K2022-09-30: $1.6M2022-12-31: $960K2023-03-31: $3.0M2023-06-30: $3.9M2023-09-30: $6.2M2023-12-31: $12.1M
The quarter ended 31 Dec 2023 against the 7 quarters before it. this quarterearliernormal: $1.6M
See the evidence (6 changes)

Short interest and volume: Short interest spike became public on 10 Feb 2024

Capricor Therapeutics had 2.7M shares sold short in the 31 Jan 2024 report, 8.2× the same report last year.

This period
2.7M (the 31 Jan 2024 report)
Normal report (median of 24 earlier)
333K
Typical spread (median absolute deviation)
68K
How far from its usual level
+23.2
Same report last year
328K
History used
2,224 days
2023-01-31: 328K2023-02-15: 311K2023-02-28: 338K2023-03-15: 353K2023-03-31: 275K2023-04-14: 264K2023-04-28: 266K2023-05-15: 295K2023-05-31: 256K2023-06-15: 258K2023-06-30: 275K2023-07-14: 274K2023-07-31: 277K2023-08-15: 315K2023-08-31: 401K2023-09-15: 548K2023-09-29: 669K2023-10-13: 1.2M2023-10-31: 1.2M2023-11-15: 1.4M2023-11-30: 1.5M2023-12-15: 2.1M2023-12-29: 2.4M2024-01-12: 2.7M2024-01-31: 2.7M
the 31 Jan 2024 report24 earlier reportsnormal: 333K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 28 Feb 2024

Capricor Therapeutics had 2.7M shares sold short in the 15 Feb 2024 report, 8.6× the same report last year.

This period
2.7M (the 15 Feb 2024 report)
Normal report (median of 24 earlier)
346K
Typical spread (median absolute deviation)
84K
How far from its usual level
+18.6
Same report last year
311K
History used
2,239 days
2023-02-15: 311K2023-02-28: 338K2023-03-15: 353K2023-03-31: 275K2023-04-14: 264K2023-04-28: 266K2023-05-15: 295K2023-05-31: 256K2023-06-15: 258K2023-06-30: 275K2023-07-14: 274K2023-07-31: 277K2023-08-15: 315K2023-08-31: 401K2023-09-15: 548K2023-09-29: 669K2023-10-13: 1.2M2023-10-31: 1.2M2023-11-15: 1.4M2023-11-30: 1.5M2023-12-15: 2.1M2023-12-29: 2.4M2024-01-12: 2.7M2024-01-31: 2.7M2024-02-15: 2.7M
the 15 Feb 2024 report24 earlier reportsnormal: 346K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly revenue change became public on 12 Mar 2024

Capricor Therapeutics reported revenue of $12.1M for the quarter ended 31 Dec 2023, 13× the same quarter last year.

This period
$12.1M (the quarter ended 31 Dec 2023)
Normal quarter (median of 7 earlier)
$1.6M
Typical spread (median absolute deviation)
$1.4M
How far from its usual level
+5.1
Same quarter last year
$960K
History used
4,567 days
2021-03-31: $41K2021-06-30: $204K2022-09-30: $1.6M2022-12-31: $960K2023-03-31: $3.0M2023-06-30: $3.9M2023-09-30: $6.2M2023-12-31: $12.1M
the quarter ended 31 Dec 20237 earlier quartersnormal: $1.6M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 12 Mar 2024

Capricor Therapeutics had 2.7M shares sold short in the 29 Feb 2024 report, 8.0× the same report last year.

This period
2.7M (the 29 Feb 2024 report)
Normal report (median of 24 earlier)
377K
Typical spread (median absolute deviation)
120K
How far from its usual level
+13.0
Same report last year
338K
History used
2,253 days
2023-02-28: 338K2023-03-15: 353K2023-03-31: 275K2023-04-14: 264K2023-04-28: 266K2023-05-15: 295K2023-05-31: 256K2023-06-15: 258K2023-06-30: 275K2023-07-14: 274K2023-07-31: 277K2023-08-15: 315K2023-08-31: 401K2023-09-15: 548K2023-09-29: 669K2023-10-13: 1.2M2023-10-31: 1.2M2023-11-15: 1.4M2023-11-30: 1.5M2023-12-15: 2.1M2023-12-29: 2.4M2024-01-12: 2.7M2024-01-31: 2.7M2024-02-15: 2.7M2024-02-29: 2.7M
the 29 Feb 2024 report24 earlier reportsnormal: 377K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 27 Mar 2024

Capricor Therapeutics had 3.2M shares sold short in the 15 Mar 2024 report, 9.1× the same report last year.

This period
3.2M (the 15 Mar 2024 report)
Normal report (median of 24 earlier)
474K
Typical spread (median absolute deviation)
213K
How far from its usual level
+8.7
Same report last year
353K
History used
2,268 days
2023-03-15: 353K2023-03-31: 275K2023-04-14: 264K2023-04-28: 266K2023-05-15: 295K2023-05-31: 256K2023-06-15: 258K2023-06-30: 275K2023-07-14: 274K2023-07-31: 277K2023-08-15: 315K2023-08-31: 401K2023-09-15: 548K2023-09-29: 669K2023-10-13: 1.2M2023-10-31: 1.2M2023-11-15: 1.4M2023-11-30: 1.5M2023-12-15: 2.1M2023-12-29: 2.4M2024-01-12: 2.7M2024-01-31: 2.7M2024-02-15: 2.7M2024-02-29: 2.7M2024-03-15: 3.2M
the 15 Mar 2024 report24 earlier reportsnormal: 474K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Apr 2024

Capricor Therapeutics had 3.5M shares sold short in the 28 Mar 2024 report, 13× the same report last year.

This period
3.5M (the 28 Mar 2024 report)
Normal report (median of 24 earlier)
608K
Typical spread (median absolute deviation)
351K
How far from its usual level
+5.6
Same report last year
275K
History used
2,281 days
2023-03-31: 275K2023-04-14: 264K2023-04-28: 266K2023-05-15: 295K2023-05-31: 256K2023-06-15: 258K2023-06-30: 275K2023-07-14: 274K2023-07-31: 277K2023-08-15: 315K2023-08-31: 401K2023-09-15: 548K2023-09-29: 669K2023-10-13: 1.2M2023-10-31: 1.2M2023-11-15: 1.4M2023-11-30: 1.5M2023-12-15: 2.1M2023-12-29: 2.4M2024-01-12: 2.7M2024-01-31: 2.7M2024-02-15: 2.7M2024-02-29: 2.7M2024-03-15: 3.2M2024-03-28: 3.5M
the 28 Mar 2024 report24 earlier reportsnormal: 608K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 26 Aug 2026Lobbying change

    registered for federal lobbying for the first time in our data (Checkmate Government Relations).

    See the evidence (1 source record)
    Source coverage starts
    3 Jan 2008
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  2. 26 Aug 2026Lobbying record

    CAPRICOR THERAPEUTICS: new lobbying registration (CHECKMATE GOVERNMENT RELATIONS) (dated 20 Jul 2026)

  3. 19 May 2026several at once

    spent $5.1M on capital projects in the quarter ended 31 Mar 2026, 5.7× the same quarter last year, while it saw 59 13F filers open a new position in the quarter ended 31 Mar 2026, 2.0× the same quarter last year. Two unrelated kinds of activity within 5 days.

    See the evidence (2 changes)

    Financials: Quarterly capital spending jump became public on 14 May 2026

    Capricor Therapeutics spent $5.1M on capital projects in the quarter ended 31 Mar 2026, 5.7× the same quarter last year.

    This period
    $5.1M (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    $388K
    Typical spread (median absolute deviation)
    $330K
    How far from its usual level
    +4.7
    Same quarter last year
    $896K
    History used
    3,652 days
    2024-03-31: $609K2024-06-30: $60K2024-09-30: $9K2024-12-31: $489K2025-03-31: $896K2025-06-30: $288K2025-09-30: $56K2025-12-31: $1.7M2026-03-31: $5.1M
    the quarter ended 31 Mar 20268 earlier quartersnormal: $388K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Institutional holdings: Many funds opening a new position became public on 15 May 2026

    Capricor Therapeutics saw 59 13F filers open a new position in the quarter ended 31 Mar 2026, 2.0× the same quarter last year.

    This period
    59 (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    27
    Typical spread (median absolute deviation)
    6
    How far from its usual level
    +3.6
    Same quarter last year
    29
    History used
    4,018 days
    2024-03-31: 252024-06-30: 182024-09-30: 252024-12-31: 442025-03-31: 292025-06-30: 142025-09-30: 302025-12-31: 402026-03-31: 59
    the quarter ended 31 Mar 20268 earlier quartersnormal: 27

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  4. 15 May 2026Institutional holdings change

    saw 59 13F filers open a new position in the quarter ended 31 Mar 2026, 2.0× the same quarter last year.

    Same quarter last year: 29; its normal quarter is 27.

    See the evidence
    This period
    59 (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    27
    Typical spread (median absolute deviation)
    6
    How far from its usual level
    +3.6
    Same quarter last year
    29
    History used
    4,018 days
    2024-03-31: 252024-06-30: 182024-09-30: 252024-12-31: 442025-03-31: 292025-06-30: 142025-09-30: 302025-12-31: 402026-03-31: 59
    the quarter ended 31 Mar 20268 earlier quartersnormal: 27

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  5. 14 May 2026Financials change

    spent $5.1M on capital projects in the quarter ended 31 Mar 2026, 5.7× the same quarter last year.

    Same quarter last year: $896K; its normal quarter is $388K.

    See the evidence
    This period
    $5.1M (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    $388K
    Typical spread (median absolute deviation)
    $330K
    How far from its usual level
    +4.7
    Same quarter last year
    $896K
    History used
    3,652 days
    2024-03-31: $609K2024-06-30: $60K2024-09-30: $9K2024-12-31: $489K2025-03-31: $896K2025-06-30: $288K2025-09-30: $56K2025-12-31: $1.7M2026-03-31: $5.1M
    the quarter ended 31 Mar 20268 earlier quartersnormal: $388K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  6. 27 May 2025Filings record

    Director or officer change

  7. 8 Apr 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  8. 8 Apr 2025Filings record

    Director or officer change

  9. 14 Feb 2025Institutional holdings change

    saw 44 13F filers open a new position in the quarter ended 31 Dec 2024, 8.8× the same quarter last year.

    Same quarter last year: 5; its normal quarter is 5.

    See the evidence
    This period
    44 (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    5
    Typical spread (median absolute deviation)
    1
    How far from its usual level
    +13.0
    Same quarter last year
    5
    History used
    3,563 days
    2022-12-31: 42023-03-31: 52023-06-30: 52023-09-30: 42023-12-31: 52024-03-31: 252024-06-30: 182024-09-30: 252024-12-31: 44
    the quarter ended 31 Dec 20248 earlier quartersnormal: 5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  10. 14 Nov 2024Institutional holdings change

    saw 25 13F filers open a new position in the quarter ended 30 Sep 2024, 6.2× the same quarter last year.

    Same quarter last year: 4; its normal quarter is 5.

    See the evidence
    This period
    25 (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    5
    Typical spread (median absolute deviation)
    0.5
    How far from its usual level
    +6.7
    Same quarter last year
    4
    History used
    3,471 days
    2022-09-30: 52022-12-31: 42023-03-31: 52023-06-30: 52023-09-30: 42023-12-31: 52024-03-31: 252024-06-30: 182024-09-30: 25
    the quarter ended 30 Sep 20248 earlier quartersnormal: 5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  11. 25 Sep 2024Insiders record

    Nippon Shinyaku Co Ltd (ten percent owner) bought 2,798,507 shares of CAPR ($15.0M) (dated 24 Sep 2024)

  12. 15 May 2024Institutional holdings change

    saw 25 13F filers open a new position in the quarter ended 31 Mar 2024, 5.0× the same quarter last year.

    Same quarter last year: 5; its normal quarter is 5.

    See the evidence
    This period
    25 (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    5
    Typical spread (median absolute deviation)
    0.5
    How far from its usual level
    +6.7
    Same quarter last year
    5
    History used
    3,288 days
    2022-03-31: 72022-06-30: 32022-09-30: 52022-12-31: 42023-03-31: 52023-06-30: 52023-09-30: 42023-12-31: 52024-03-31: 25
    the quarter ended 31 Mar 20248 earlier quartersnormal: 5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  13. 10 Apr 2024Short interest and volume change

    had 3.5M shares sold short in the 28 Mar 2024 report, 13× the same report last year.

    Same report last year: 275K; its normal report is 608K.

    See the evidence
    This period
    3.5M (the 28 Mar 2024 report)
    Normal report (median of 24 earlier)
    608K
    Typical spread (median absolute deviation)
    351K
    How far from its usual level
    +5.6
    Same report last year
    275K
    History used
    2,281 days
    2023-03-31: 275K2023-04-14: 264K2023-04-28: 266K2023-05-15: 295K2023-05-31: 256K2023-06-15: 258K2023-06-30: 275K2023-07-14: 274K2023-07-31: 277K2023-08-15: 315K2023-08-31: 401K2023-09-15: 548K2023-09-29: 669K2023-10-13: 1.2M2023-10-31: 1.2M2023-11-15: 1.4M2023-11-30: 1.5M2023-12-15: 2.1M2023-12-29: 2.4M2024-01-12: 2.7M2024-01-31: 2.7M2024-02-15: 2.7M2024-02-29: 2.7M2024-03-15: 3.2M2024-03-28: 3.5M
    the 28 Mar 2024 report24 earlier reportsnormal: 608K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  14. 27 Mar 2024Short interest and volume change

    had 3.2M shares sold short in the 15 Mar 2024 report, 9.1× the same report last year.

    Same report last year: 353K; its normal report is 474K.

    See the evidence
    This period
    3.2M (the 15 Mar 2024 report)
    Normal report (median of 24 earlier)
    474K
    Typical spread (median absolute deviation)
    213K
    How far from its usual level
    +8.7
    Same report last year
    353K
    History used
    2,268 days
    2023-03-15: 353K2023-03-31: 275K2023-04-14: 264K2023-04-28: 266K2023-05-15: 295K2023-05-31: 256K2023-06-15: 258K2023-06-30: 275K2023-07-14: 274K2023-07-31: 277K2023-08-15: 315K2023-08-31: 401K2023-09-15: 548K2023-09-29: 669K2023-10-13: 1.2M2023-10-31: 1.2M2023-11-15: 1.4M2023-11-30: 1.5M2023-12-15: 2.1M2023-12-29: 2.4M2024-01-12: 2.7M2024-01-31: 2.7M2024-02-15: 2.7M2024-02-29: 2.7M2024-03-15: 3.2M
    the 15 Mar 2024 report24 earlier reportsnormal: 474K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  15. 12 Mar 2024several at once

    reported revenue of $12.1M for the quarter ended 31 Dec 2023, 13× the same quarter last year, while it had 3.2M shares sold short in the 15 Mar 2024 report, 9.1× the same report last year. Two unrelated kinds of activity within 63 days.

    See the evidence (6 changes)

    Short interest and volume: Short interest spike became public on 10 Feb 2024

    Capricor Therapeutics had 2.7M shares sold short in the 31 Jan 2024 report, 8.2× the same report last year.

    This period
    2.7M (the 31 Jan 2024 report)
    Normal report (median of 24 earlier)
    333K
    Typical spread (median absolute deviation)
    68K
    How far from its usual level
    +23.2
    Same report last year
    328K
    History used
    2,224 days
    2023-01-31: 328K2023-02-15: 311K2023-02-28: 338K2023-03-15: 353K2023-03-31: 275K2023-04-14: 264K2023-04-28: 266K2023-05-15: 295K2023-05-31: 256K2023-06-15: 258K2023-06-30: 275K2023-07-14: 274K2023-07-31: 277K2023-08-15: 315K2023-08-31: 401K2023-09-15: 548K2023-09-29: 669K2023-10-13: 1.2M2023-10-31: 1.2M2023-11-15: 1.4M2023-11-30: 1.5M2023-12-15: 2.1M2023-12-29: 2.4M2024-01-12: 2.7M2024-01-31: 2.7M
    the 31 Jan 2024 report24 earlier reportsnormal: 333K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 28 Feb 2024

    Capricor Therapeutics had 2.7M shares sold short in the 15 Feb 2024 report, 8.6× the same report last year.

    This period
    2.7M (the 15 Feb 2024 report)
    Normal report (median of 24 earlier)
    346K
    Typical spread (median absolute deviation)
    84K
    How far from its usual level
    +18.6
    Same report last year
    311K
    History used
    2,239 days
    2023-02-15: 311K2023-02-28: 338K2023-03-15: 353K2023-03-31: 275K2023-04-14: 264K2023-04-28: 266K2023-05-15: 295K2023-05-31: 256K2023-06-15: 258K2023-06-30: 275K2023-07-14: 274K2023-07-31: 277K2023-08-15: 315K2023-08-31: 401K2023-09-15: 548K2023-09-29: 669K2023-10-13: 1.2M2023-10-31: 1.2M2023-11-15: 1.4M2023-11-30: 1.5M2023-12-15: 2.1M2023-12-29: 2.4M2024-01-12: 2.7M2024-01-31: 2.7M2024-02-15: 2.7M
    the 15 Feb 2024 report24 earlier reportsnormal: 346K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Financials: Quarterly revenue change became public on 12 Mar 2024

    Capricor Therapeutics reported revenue of $12.1M for the quarter ended 31 Dec 2023, 13× the same quarter last year.

    This period
    $12.1M (the quarter ended 31 Dec 2023)
    Normal quarter (median of 7 earlier)
    $1.6M
    Typical spread (median absolute deviation)
    $1.4M
    How far from its usual level
    +5.1
    Same quarter last year
    $960K
    History used
    4,567 days
    2021-03-31: $41K2021-06-30: $204K2022-09-30: $1.6M2022-12-31: $960K2023-03-31: $3.0M2023-06-30: $3.9M2023-09-30: $6.2M2023-12-31: $12.1M
    the quarter ended 31 Dec 20237 earlier quartersnormal: $1.6M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Short interest and volume: Short interest spike became public on 12 Mar 2024

    Capricor Therapeutics had 2.7M shares sold short in the 29 Feb 2024 report, 8.0× the same report last year.

    This period
    2.7M (the 29 Feb 2024 report)
    Normal report (median of 24 earlier)
    377K
    Typical spread (median absolute deviation)
    120K
    How far from its usual level
    +13.0
    Same report last year
    338K
    History used
    2,253 days
    2023-02-28: 338K2023-03-15: 353K2023-03-31: 275K2023-04-14: 264K2023-04-28: 266K2023-05-15: 295K2023-05-31: 256K2023-06-15: 258K2023-06-30: 275K2023-07-14: 274K2023-07-31: 277K2023-08-15: 315K2023-08-31: 401K2023-09-15: 548K2023-09-29: 669K2023-10-13: 1.2M2023-10-31: 1.2M2023-11-15: 1.4M2023-11-30: 1.5M2023-12-15: 2.1M2023-12-29: 2.4M2024-01-12: 2.7M2024-01-31: 2.7M2024-02-15: 2.7M2024-02-29: 2.7M
    the 29 Feb 2024 report24 earlier reportsnormal: 377K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 27 Mar 2024

    Capricor Therapeutics had 3.2M shares sold short in the 15 Mar 2024 report, 9.1× the same report last year.

    This period
    3.2M (the 15 Mar 2024 report)
    Normal report (median of 24 earlier)
    474K
    Typical spread (median absolute deviation)
    213K
    How far from its usual level
    +8.7
    Same report last year
    353K
    History used
    2,268 days
    2023-03-15: 353K2023-03-31: 275K2023-04-14: 264K2023-04-28: 266K2023-05-15: 295K2023-05-31: 256K2023-06-15: 258K2023-06-30: 275K2023-07-14: 274K2023-07-31: 277K2023-08-15: 315K2023-08-31: 401K2023-09-15: 548K2023-09-29: 669K2023-10-13: 1.2M2023-10-31: 1.2M2023-11-15: 1.4M2023-11-30: 1.5M2023-12-15: 2.1M2023-12-29: 2.4M2024-01-12: 2.7M2024-01-31: 2.7M2024-02-15: 2.7M2024-02-29: 2.7M2024-03-15: 3.2M
    the 15 Mar 2024 report24 earlier reportsnormal: 474K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 10 Apr 2024

    Capricor Therapeutics had 3.5M shares sold short in the 28 Mar 2024 report, 13× the same report last year.

    This period
    3.5M (the 28 Mar 2024 report)
    Normal report (median of 24 earlier)
    608K
    Typical spread (median absolute deviation)
    351K
    How far from its usual level
    +5.6
    Same report last year
    275K
    History used
    2,281 days
    2023-03-31: 275K2023-04-14: 264K2023-04-28: 266K2023-05-15: 295K2023-05-31: 256K2023-06-15: 258K2023-06-30: 275K2023-07-14: 274K2023-07-31: 277K2023-08-15: 315K2023-08-31: 401K2023-09-15: 548K2023-09-29: 669K2023-10-13: 1.2M2023-10-31: 1.2M2023-11-15: 1.4M2023-11-30: 1.5M2023-12-15: 2.1M2023-12-29: 2.4M2024-01-12: 2.7M2024-01-31: 2.7M2024-02-15: 2.7M2024-02-29: 2.7M2024-03-15: 3.2M2024-03-28: 3.5M
    the 28 Mar 2024 report24 earlier reportsnormal: 608K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  16. 12 Mar 2024Short interest and volume change

    had 2.7M shares sold short in the 29 Feb 2024 report, 8.0× the same report last year.

    Same report last year: 338K; its normal report is 377K.

    See the evidence
    This period
    2.7M (the 29 Feb 2024 report)
    Normal report (median of 24 earlier)
    377K
    Typical spread (median absolute deviation)
    120K
    How far from its usual level
    +13.0
    Same report last year
    338K
    History used
    2,253 days
    2023-02-28: 338K2023-03-15: 353K2023-03-31: 275K2023-04-14: 264K2023-04-28: 266K2023-05-15: 295K2023-05-31: 256K2023-06-15: 258K2023-06-30: 275K2023-07-14: 274K2023-07-31: 277K2023-08-15: 315K2023-08-31: 401K2023-09-15: 548K2023-09-29: 669K2023-10-13: 1.2M2023-10-31: 1.2M2023-11-15: 1.4M2023-11-30: 1.5M2023-12-15: 2.1M2023-12-29: 2.4M2024-01-12: 2.7M2024-01-31: 2.7M2024-02-15: 2.7M2024-02-29: 2.7M
    the 29 Feb 2024 report24 earlier reportsnormal: 377K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 12 Mar 2024Financials change

    reported revenue of $12.1M for the quarter ended 31 Dec 2023, 13× the same quarter last year.

    Same quarter last year: $960K; its normal quarter is $1.6M.

    See the evidence
    This period
    $12.1M (the quarter ended 31 Dec 2023)
    Normal quarter (median of 7 earlier)
    $1.6M
    Typical spread (median absolute deviation)
    $1.4M
    How far from its usual level
    +5.1
    Same quarter last year
    $960K
    History used
    4,567 days
    2021-03-31: $41K2021-06-30: $204K2022-09-30: $1.6M2022-12-31: $960K2023-03-31: $3.0M2023-06-30: $3.9M2023-09-30: $6.2M2023-12-31: $12.1M
    the quarter ended 31 Dec 20237 earlier quartersnormal: $1.6M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  18. 28 Feb 2024Short interest and volume change

    had 2.7M shares sold short in the 15 Feb 2024 report, 8.6× the same report last year.

    Same report last year: 311K; its normal report is 346K.

    See the evidence
    This period
    2.7M (the 15 Feb 2024 report)
    Normal report (median of 24 earlier)
    346K
    Typical spread (median absolute deviation)
    84K
    How far from its usual level
    +18.6
    Same report last year
    311K
    History used
    2,239 days
    2023-02-15: 311K2023-02-28: 338K2023-03-15: 353K2023-03-31: 275K2023-04-14: 264K2023-04-28: 266K2023-05-15: 295K2023-05-31: 256K2023-06-15: 258K2023-06-30: 275K2023-07-14: 274K2023-07-31: 277K2023-08-15: 315K2023-08-31: 401K2023-09-15: 548K2023-09-29: 669K2023-10-13: 1.2M2023-10-31: 1.2M2023-11-15: 1.4M2023-11-30: 1.5M2023-12-15: 2.1M2023-12-29: 2.4M2024-01-12: 2.7M2024-01-31: 2.7M2024-02-15: 2.7M
    the 15 Feb 2024 report24 earlier reportsnormal: 346K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  19. 10 Feb 2024Short interest and volume change

    had 2.7M shares sold short in the 31 Jan 2024 report, 8.2× the same report last year.

    Same report last year: 328K; its normal report is 333K.

    See the evidence
    This period
    2.7M (the 31 Jan 2024 report)
    Normal report (median of 24 earlier)
    333K
    Typical spread (median absolute deviation)
    68K
    How far from its usual level
    +23.2
    Same report last year
    328K
    History used
    2,224 days
    2023-01-31: 328K2023-02-15: 311K2023-02-28: 338K2023-03-15: 353K2023-03-31: 275K2023-04-14: 264K2023-04-28: 266K2023-05-15: 295K2023-05-31: 256K2023-06-15: 258K2023-06-30: 275K2023-07-14: 274K2023-07-31: 277K2023-08-15: 315K2023-08-31: 401K2023-09-15: 548K2023-09-29: 669K2023-10-13: 1.2M2023-10-31: 1.2M2023-11-15: 1.4M2023-11-30: 1.5M2023-12-15: 2.1M2023-12-29: 2.4M2024-01-12: 2.7M2024-01-31: 2.7M
    the 31 Jan 2024 report24 earlier reportsnormal: 333K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  20. 25 Jan 2024Short interest and volume change

    had 2.7M shares sold short in the 12 Jan 2024 report, 7.8× the same report last year.

    Same report last year: 343K; its normal report is 333K.

    See the evidence
    This period
    2.7M (the 12 Jan 2024 report)
    Normal report (median of 24 earlier)
    333K
    Typical spread (median absolute deviation)
    68K
    How far from its usual level
    +23.4
    Same report last year
    343K
    History used
    2,205 days
    2023-01-13: 343K2023-01-31: 328K2023-02-15: 311K2023-02-28: 338K2023-03-15: 353K2023-03-31: 275K2023-04-14: 264K2023-04-28: 266K2023-05-15: 295K2023-05-31: 256K2023-06-15: 258K2023-06-30: 275K2023-07-14: 274K2023-07-31: 277K2023-08-15: 315K2023-08-31: 401K2023-09-15: 548K2023-09-29: 669K2023-10-13: 1.2M2023-10-31: 1.2M2023-11-15: 1.4M2023-11-30: 1.5M2023-12-15: 2.1M2023-12-29: 2.4M2024-01-12: 2.7M
    the 12 Jan 2024 report24 earlier reportsnormal: 333K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  21. 11 Jan 2024Short interest and volume change

    had 2.4M shares sold short in the 29 Dec 2023 report, 6.9× the same report last year.

    Same report last year: 341K; its normal report is 333K.

    See the evidence
    This period
    2.4M (the 29 Dec 2023 report)
    Normal report (median of 24 earlier)
    333K
    Typical spread (median absolute deviation)
    63K
    How far from its usual level
    +21.5
    Same report last year
    341K
    History used
    2,191 days
    2022-12-30: 341K2023-01-13: 343K2023-01-31: 328K2023-02-15: 311K2023-02-28: 338K2023-03-15: 353K2023-03-31: 275K2023-04-14: 264K2023-04-28: 266K2023-05-15: 295K2023-05-31: 256K2023-06-15: 258K2023-06-30: 275K2023-07-14: 274K2023-07-31: 277K2023-08-15: 315K2023-08-31: 401K2023-09-15: 548K2023-09-29: 669K2023-10-13: 1.2M2023-10-31: 1.2M2023-11-15: 1.4M2023-11-30: 1.5M2023-12-15: 2.1M2023-12-29: 2.4M
    the 29 Dec 2023 report24 earlier reportsnormal: 333K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 28 Dec 2023Short interest and volume change

    had 2.1M shares sold short in the 15 Dec 2023 report, 6.8× the same report last year.

    Same report last year: 312K; its normal report is 322K.

    See the evidence
    This period
    2.1M (the 15 Dec 2023 report)
    Normal report (median of 24 earlier)
    322K
    Typical spread (median absolute deviation)
    47K
    How far from its usual level
    +25.7
    Same report last year
    312K
    History used
    2,177 days
    2022-12-15: 312K2022-12-30: 341K2023-01-13: 343K2023-01-31: 328K2023-02-15: 311K2023-02-28: 338K2023-03-15: 353K2023-03-31: 275K2023-04-14: 264K2023-04-28: 266K2023-05-15: 295K2023-05-31: 256K2023-06-15: 258K2023-06-30: 275K2023-07-14: 274K2023-07-31: 277K2023-08-15: 315K2023-08-31: 401K2023-09-15: 548K2023-09-29: 669K2023-10-13: 1.2M2023-10-31: 1.2M2023-11-15: 1.4M2023-11-30: 1.5M2023-12-15: 2.1M
    the 15 Dec 2023 report24 earlier reportsnormal: 322K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 12 Dec 2023Short interest and volume change

    had 1.5M shares sold short in the 30 Nov 2023 report, 6.1× the same report last year.

    Same report last year: 238K; its normal report is 314K.

    See the evidence
    This period
    1.5M (the 30 Nov 2023 report)
    Normal report (median of 24 earlier)
    314K
    Typical spread (median absolute deviation)
    40K
    How far from its usual level
    +19.6
    Same report last year
    238K
    History used
    2,162 days
    2022-11-30: 238K2022-12-15: 312K2022-12-30: 341K2023-01-13: 343K2023-01-31: 328K2023-02-15: 311K2023-02-28: 338K2023-03-15: 353K2023-03-31: 275K2023-04-14: 264K2023-04-28: 266K2023-05-15: 295K2023-05-31: 256K2023-06-15: 258K2023-06-30: 275K2023-07-14: 274K2023-07-31: 277K2023-08-15: 315K2023-08-31: 401K2023-09-15: 548K2023-09-29: 669K2023-10-13: 1.2M2023-10-31: 1.2M2023-11-15: 1.4M2023-11-30: 1.5M
    the 30 Nov 2023 report24 earlier reportsnormal: 314K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 28 Nov 2023Short interest and volume change

    had 1.4M shares sold short in the 15 Nov 2023 report, 5.2× the same report last year.

    Same report last year: 261K; its normal report is 311K.

    See the evidence
    This period
    1.4M (the 15 Nov 2023 report)
    Normal report (median of 24 earlier)
    311K
    Typical spread (median absolute deviation)
    40K
    How far from its usual level
    +18.0
    Same report last year
    261K
    History used
    2,147 days
    2022-11-15: 261K2022-11-30: 238K2022-12-15: 312K2022-12-30: 341K2023-01-13: 343K2023-01-31: 328K2023-02-15: 311K2023-02-28: 338K2023-03-15: 353K2023-03-31: 275K2023-04-14: 264K2023-04-28: 266K2023-05-15: 295K2023-05-31: 256K2023-06-15: 258K2023-06-30: 275K2023-07-14: 274K2023-07-31: 277K2023-08-15: 315K2023-08-31: 401K2023-09-15: 548K2023-09-29: 669K2023-10-13: 1.2M2023-10-31: 1.2M2023-11-15: 1.4M
    the 15 Nov 2023 report24 earlier reportsnormal: 311K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 10 Nov 2023Short interest and volume change

    had 1.2M shares sold short in the 31 Oct 2023 report, 5.0× the same report last year.

    Same report last year: 248K; its normal report is 303K.

    See the evidence
    This period
    1.2M (the 31 Oct 2023 report)
    Normal report (median of 24 earlier)
    303K
    Typical spread (median absolute deviation)
    38K
    How far from its usual level
    +16.4
    Same report last year
    248K
    History used
    2,132 days
    2022-10-31: 248K2022-11-15: 261K2022-11-30: 238K2022-12-15: 312K2022-12-30: 341K2023-01-13: 343K2023-01-31: 328K2023-02-15: 311K2023-02-28: 338K2023-03-15: 353K2023-03-31: 275K2023-04-14: 264K2023-04-28: 266K2023-05-15: 295K2023-05-31: 256K2023-06-15: 258K2023-06-30: 275K2023-07-14: 274K2023-07-31: 277K2023-08-15: 315K2023-08-31: 401K2023-09-15: 548K2023-09-29: 669K2023-10-13: 1.2M2023-10-31: 1.2M
    the 31 Oct 2023 report24 earlier reportsnormal: 303K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 25 Oct 2023Short interest and volume change

    had 1.2M shares sold short in the 13 Oct 2023 report, 4.1× the same report last year.

    Same report last year: 298K; its normal report is 296K.

    See the evidence
    This period
    1.2M (the 13 Oct 2023 report)
    Normal report (median of 24 earlier)
    296K
    Typical spread (median absolute deviation)
    34K
    How far from its usual level
    +18.2
    Same report last year
    298K
    History used
    2,114 days
    2022-10-14: 298K2022-10-31: 248K2022-11-15: 261K2022-11-30: 238K2022-12-15: 312K2022-12-30: 341K2023-01-13: 343K2023-01-31: 328K2023-02-15: 311K2023-02-28: 338K2023-03-15: 353K2023-03-31: 275K2023-04-14: 264K2023-04-28: 266K2023-05-15: 295K2023-05-31: 256K2023-06-15: 258K2023-06-30: 275K2023-07-14: 274K2023-07-31: 277K2023-08-15: 315K2023-08-31: 401K2023-09-15: 548K2023-09-29: 669K2023-10-13: 1.2M
    the 13 Oct 2023 report24 earlier reportsnormal: 296K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  27. 14 Oct 2023Insiders record

    Musket David B (director) bought 410 shares of CAPR ($1,128) (dated 13 Oct 2023)

  28. 13 Oct 2023Insiders record

    COLLIER EARL M JR (director) bought 10,000 shares of CAPR ($28,300) (dated 12 Oct 2023)

  29. 12 Oct 2023Short interest and volume change

    had 669K shares sold short in the 29 Sep 2023 report, 2.0× the same report last year.

    Same report last year: 331K; its normal report is 296K.

    See the evidence
    This period
    669K (the 29 Sep 2023 report)
    Normal report (median of 24 earlier)
    296K
    Typical spread (median absolute deviation)
    33K
    How far from its usual level
    +7.5
    Same report last year
    331K
    History used
    2,100 days
    2022-09-30: 331K2022-10-14: 298K2022-10-31: 248K2022-11-15: 261K2022-11-30: 238K2022-12-15: 312K2022-12-30: 341K2023-01-13: 343K2023-01-31: 328K2023-02-15: 311K2023-02-28: 338K2023-03-15: 353K2023-03-31: 275K2023-04-14: 264K2023-04-28: 266K2023-05-15: 295K2023-05-31: 256K2023-06-15: 258K2023-06-30: 275K2023-07-14: 274K2023-07-31: 277K2023-08-15: 315K2023-08-31: 401K2023-09-15: 548K2023-09-29: 669K
    the 29 Sep 2023 report24 earlier reportsnormal: 296K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 12 Oct 2023Insiders record

    Musket David B (director) bought 5,083 shares of CAPR ($14,334) (dated 11 Oct 2023)

  31. 11 Oct 2023Insiders record

    Auwaerter Paul Gisbert (director) bought 5,000 shares of CAPR ($14,200) (dated 10 Oct 2023)

  32. 7 Oct 2023Insiders record

    Musket David B (director) bought 2,500 shares of CAPR ($7,250) (dated 6 Oct 2023)

  33. 27 Sep 2023Short interest and volume change

    had 548K shares sold short in the 15 Sep 2023 report, 2.6× the same report last year.

    Same report last year: 213K; its normal report is 286K.

    See the evidence
    This period
    548K (the 15 Sep 2023 report)
    Normal report (median of 24 earlier)
    286K
    Typical spread (median absolute deviation)
    28K
    How far from its usual level
    +5.2
    Same report last year
    213K
    History used
    2,086 days
    2022-09-15: 213K2022-09-30: 331K2022-10-14: 298K2022-10-31: 248K2022-11-15: 261K2022-11-30: 238K2022-12-15: 312K2022-12-30: 341K2023-01-13: 343K2023-01-31: 328K2023-02-15: 311K2023-02-28: 338K2023-03-15: 353K2023-03-31: 275K2023-04-14: 264K2023-04-28: 266K2023-05-15: 295K2023-05-31: 256K2023-06-15: 258K2023-06-30: 275K2023-07-14: 274K2023-07-31: 277K2023-08-15: 315K2023-08-31: 401K2023-09-15: 548K
    the 15 Sep 2023 report24 earlier reportsnormal: 286K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  34. 6 Sep 2023Filings record

    Director or officer change

  35. 24 Jul 2023Filings record

    Director or officer change

  36. 13 Jul 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  37. 13 Jul 2023Filings record

    Director or officer change

  38. 8 Jul 2022Insiders record

    Avat Xavier (CHIEF BUSINESS OFFICER) bought 2,500 shares of CAPR ($9,320) (dated 7 Jul 2022)

  39. 27 Jul 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  40. 27 Jul 2021Filings record

    Director or officer change

Showing the newest 40 of 79 entries; narrow the window or the kind of data to see older ones.

Not listed: 162 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001133869
Ticker
CAPR
Domain
capricor.com
Employer name
Capricor Therapeutics, Inc. (1 unverified)
Hq location
CA|SAN DIEGO|92121 (1 unverified)
Lobbying client
capricor therapeutics
Name
Capricor Therapeutics Inc, Nile Therapeutics, Inc., SMI PRODUCTS INC
  • DOL H-1B labor condition applications and PERM certifications11 data points24 Aug 2020 to 15 Mar 2021
  • Federal lobbying disclosures (LDA)1 record, 3 data points20 Jul 2026 to 30 Sep 2026
  • SEC Form 13F institutional holdings423 data points31 Mar 2015 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)171 records22 Feb 2016 to 10 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)996 data points4 Jul 2005 to 9 Nov 2026
  • SEC Form 4 insider transactions33 records, 76 data points18 Mar 2016 to 29 Jun 2026
  • FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4176 data points1 Aug 2018 to 20 Nov 2026